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The objective of this thesis was to determine the role of nonadrenergic vasoactive 
substances in the control of blood flow in the elderly. The first study aimed to determine 
the individual and potentiating effects of the renin-angiotensin-aldosterone (RAAS) and 
alpha-adrenergic systems on the regulation of blood flow in the young and old. We 
observed an enhanced maximal reduction in brachial artery blood flow in response to 
angiotensin-II (ANG-II) in the old compared to the young, which was abolished when the 
alpha-adrenergic component of the response was pharmacologically eliminated with 
phentolamine. These data suggest that with healthy aging, the increased ANG-II-
mediated vasoconstriction may be attributed, in part, to potentiation of alpha-adrenergic 
vasoconstriction, and indicates that the “cross-talk” between the RAAS and adrenergic 
systems could be an important therapeutic consideration for hypertension in the elderly.  
The second study of this project was focused on the role of endogenous endothelin-1 
(ET-1) in the regulation of vascular tone at rest and during exercise, with a secondary 
emphasis on how this pathway is altered with advancing age. The first portion of the 
second study thus sought to characterize the role of ET-1 on blood flow, arterial blood 
pressure, and oxygen consumption (VO2) during knee extensor exercise in young, healthy 
adults. This study documented an increase in exercising limb blood flow following ET-1 
receptor subtype A (ETA) antagonism (BQ-123), which was accompanied by a decrement 
in arterial blood pressure and an increase in VO2. Together, these findings have identified 
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a significant role of the ET-1 pathway in the cardiovascular response to exercise, 
implicating vasoconstriction via the ETA receptor as an important mechanism for both 
restraint of blood flow in the exercising limb and support of arterial blood pressure in 
healthy, young adults. During the aging portion of the second study, at rest, blood flow 
was reduced by 30% in the elderly compared to the young. ETA antagonism did not 
change resting blood flow in the young, but restored blood flow in the old to a level 
similar to that of the young. During exercise, BQ-123 increased blood flow and VO2 to a 
similar degree in both the young and old. Likewise, the increase in arterial blood pressure 
during exercise was attenuated in a similar manner between groups after BQ-123 
administration. Together these findings demonstrate differences in the regulatory role of 
the ET-1 pathway at rest and exercise with advancing age. Collectively, these studies 
have provided insight into the role of nonadrenergic vasoactive substances, specifically 
ANG-II and ET-1, in the regulation of vascular tone with age. Findings from these 
studies may provide new information concerning the prevention and treatment of age-
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In the United States, cardiovascular diseases such as atherosclerosis and 
hypertension, which can both lead to the development of heart failure and stroke, are the 
leading cause of mortality, accounting for upwards of 40% of deaths in those 65 and 
older (16). Since over 80% of cardiovascular deaths occur within this age-range (16), age 
may be considered a risk factor for cardiovascular disease (14). With aging, there are 
adverse alterations to the cardiovascular system, both structurally and functionally, which 
jointly have been thought to play a role in the progression of cardiovascular disease.  One 
principle alteration associated with  the age-related changes of the cardiovascular system 
is an elevation in vascular tone (8, 32), which likely contributes to the attenuated skeletal 
muscle blood flow observed at rest in the elderly (7, 25, 26).   
Age-related changes in vascular tone may be particularly important in the 
cardiovascular response to exercise, when muscle perfusion must increase dramatically to 
meet the elevated metabolic demand of the exercising tissue. This increase in skeletal 
muscle blood flow during exercise is accomplished, in large part, by metabolic 
vasodilation within the skeletal muscle vasculature, though this response must be 
balanced by the concomitant need to support arterial blood pressure. There is some 
evidence for impaired hyperemia during leg exercise in the elderly (15, 25, 27, 36), yet 
very few studies to date have taken an integrative approach to examine changes in the 
“balancing act” between maintenance of skeletal muscle blood flow and arterial blood 
pressure during exercise in this cohort. Further, the potential mechanisms responsible for 
age-related dysregulation of vascular tone during exercise remain poorly understood.  
One of the most pronounced and reproducible autonomic adaptations associated 
with healthy aging is a progressive increase in firing of sympathetic nerves innervating 
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skeletal muscle vascular beds (6, 22, 32). Accompanying this age-associated rise in 
muscle sympathetic nerve activity (MSNA) is a selective reduction in alpha-adrenergic 
responsiveness (8), presumably due to a down regulation or desensitization of alpha-
adrenergic receptors. However, nonspecific alpha-adrenergic blockade does not fully 
restore blood flow to that of the young (8). This indicates that sympathetic-adrenergic 
receptor-mediated control of local skeletal muscle vascular tone is not solely responsible 
for the reduction in skeletal muscle blood flow in the elderly, presenting the possibility 
for age-related changes in nonadrenergic vasoconstrictor pathways.  
Although there are an abundance of vasoactive molecules that might contribute to 
the vasoconstriction observed at rest and during physical activity in the elderly, the age-
associated alterations in angiotensin-II (ANG-II) and endothelin-1 (ET-1) represent two 
potentially significant and somewhat understudied pathways that may contribute to the 
elevated vascular tone documented with age.  ANG-II is the end-product of the renin-
angiotensin-aldosterone system (RAAS), and functions in an endocrine manner as a 
potent endogenous vasoconstrictor through binding to the  ANG-II subtype 1 (AT1) 
receptors on arteriolar vascular smooth muscle (12), as  well as potentiating 
norepinephrine (NE) release from sympathetic butons by binding to AT1 receptors 
prejunctionally (4). ANG-II subtype 2 (AT2) receptors are also present in human arteries 
(19, 38), though recent studies suggest that this ANG-II receptor subtype plays a minimal 
role in blood flow regulation in humans (10). While there are multiple places within the 
RAAS pathway that can potentially serve to regulate ANG-II production, one of the 
essential steps is the secretion of renin from the kidneys (2), which is initiated by an 
increase in sympathetic nerve activity (SNA) (11, 24, 28). Thus, it is plausible that the 
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inherent elevation in SNA with aging (6, 22, 32) expressed at the juxtaglomerular cells 
could increase renin production, increase the concentration of circulating ANG-II, and 
ultimately amplify alpha-adrenergic vasoconstriction via circulating ANG-II. The unique 
nature of the AT1 receptors involvement in the regulation of the sympathetic nervous 
system (SNS) and RAAS make it an ideal site to investigate the interactions between 
these two respective systems and their collective contribution in regulating peripheral 
hemodynamics in the elderly. 
While aging individuals have similar sympatho-adjustments to stressors which 
acutely increase SNA, such as static and dynamic exercise, (20, 29), the increase in 
peripheral vascular tone due to the interactions between the SNS and RAAS could 
account for a portion of the age-related attenuation in peripheral blood flow. Indeed, the 
documentation that AT1 receptor density has been shown to increase with age (9, 31), and 
functional studies from our group identifying an age-associated increase in ANG-II-
mediated vasoconstriction in the leg (36), affirm the significance of AT1 receptors in the 
regulation of peripheral vascular tone. However, it is unknown whether the enhanced 
ANG-II-mediated vasoconstriction demonstrated in the elderly is predominately due to a 
hypersensitivity of the postjunctional AT1 receptors or due to an enhanced ANG-II 
potentiated NE release. Thus, the first objective of this thesis was to determine the role of 
peripheral AT1 receptors in the regulation of sympathetic vasoconstriction, and whether 
this differs with healthy aging.  
Unlike ANG-II, ET-1 acts primarily in a paracrine and autocrine manner, 
produced by the vascular endothelial cells and binding to the ETA receptor subtype, 
located on the vascular smooth muscle, and the ETB receptor subtype, located on the 
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vascular endothelium (1, 37).  While ANG-II production is directly linked to the SNS, 
stimulation of ET-1 production by the vascular endothelial cells occurs locally by 
vasoactive hormones, shear stress, free radicals, and hypoxia, and is inhibited by stimuli 
that increase concentrations of cyclic GMP  such as nitric oxide and prostaglandins (13). 
However, despite the distinct differences in stimuli inducing the production of ANG-II 
and ET-1, the G-protein-coupled receptor pathway leading to ETA receptor-mediated 
vasoconstriction is similar to that of the AT1 receptor (3, 30). Thus, the examination of 
these two nonadrenergic receptors in conjunction with one another provides the ability to 
distinguish between a receptor specific versus a G-protein-linked response.  
As ET-1 has been identified as one of the most potent endogenous vasoconstrictor 
substances (23), any age-related adaptation in the sensitivity of ETA and ETB receptors 
could profoundly alter peripheral vascular tone and ultimately skeletal muscle blood 
flow. Recently, it was reported that ET-1-mediated vasoconstriction of the brachial artery 
at rest is significantly attenuated in the elderly, while ETA receptor blockade (BQ-123) 
enhanced resting blood flow in older individuals, compared to their younger counterparts 
who exhibited no change in blood flow (33). Also, ETA receptor blockade has been 
shown to enhance vasodilation induced by acetylcholine infusion in older individuals, 
indicating that an age-related increase in endogenous  ET-1  may be partially responsible 
for the reduction in endothelial-dependent vasodilation in the elderly (34). These findings 
support the notion that there is a concomitant age-associated increase in circulating ET-1, 
which may ultimately contribute to the elevated resting vasoconstrictor tone and impaired 
vasodilatory capacity in the elderly. However, the importance of ET-1 during exercise 
remains unknown.  
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Initial evidence suggesting a contributing role of ET-1 in the regulation of skeletal 
muscle blood flow during exercise has been derived, for the most part, from assays 
measuring circulating concentrations of plasma ET-1 during exercise.  With evidence 
supporting (18), and refuting (5, 17), increasing concentrations of ET-1 during exercise. 
Previous work in animals has evaluated the tonic ET-1-mediated restraint on vascular 
tone via ETA and concomitant ETA/ETB receptor blockade during exercise, and reported 
that ETA receptor inhibition improved exercising muscle blood flow (21). Recently, our 
group identified an attenuated vasoconstriction in response to intra-arterial infusion of 
ET-1 during dynamic knee-extensor exercise in young, healthy humans. (35). However, 
the role of endogenous ET-1, specifically the ETA receptor, in the regulation of exercising 
limb blood flow and arterial blood pressure has yet to be investigated. Thus, the second 
objective of this thesis was to further elucidate the role of ET-1 in the regulation of 
vascular tone in young healthy individuals during exercise, and second, determine the 
extent to which this vasoconstrictor pathway contributes to age-associated differences in 
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Aging is characterized by a global sympathoexcitation, expressed through both 
the alpha-adrenergic and renin-angiotensin-aldosterone (RAAS) pathways. Overactivity 
of these pathways may contribute to the well-known elevation in peripheral 
vasoconstriction with age, as well as the sequelae of geriatric hypertension. To examine 
the individual and possible potentiating effects of these two pathways, 14 subjects (n = 8 
young, 26±1 yrs; n = 6 old, 68±3 yrs) underwent brachial artery (BA) catheterization for 
local administration of angiotensin-II (ANG-II) (0.8-25.6 ng/dl/min), norepinephrine 
(NE) (2.5-80 ng/dl/min) and ANG-II with concomitant alpha-adrenergic antagonism 
(phentolamine (PHEN), 10 µg/dl/min). Ultrasound Doppler was utilized to determine BA 
blood flow in both the infused and contralateral (control) limb. Arterial blood pressure 
was measured directly and heart rate was determined via standard three-lead ECG. At 
maximal doses, the ANG-II-mediated reduction in BA blood flow was greater in the old 
(-61±6%) compared to young (-48±4%, P = 0.01), while the NE-mediated reduction in 
BA blood flow was similar between groups (-58±9% old, -65±7% young). In the 
presence of PHEN, the ANG-II-mediated reduction in BA blood flow in the old was 
restored to that of the young (-43±8% old, -39±6% young). Arterial blood pressure, heart 
rate, and control arm BA blood flow remained unchanged throughout all drug infusions. 
These data suggest that with healthy aging, the increased ANG-II-mediated reduction in 
blood flow may be attributed, in part, to potentiation of alpha-adrenergic reduction in 
blood flow, and indicate that “cross-talk” between the RAAS and adrenergic systems 





One principle alteration associated with age-related changes of the cardiovascular 
system is an elevation in vascular tone (8, 31), which likely contributes to the attenuated 
skeletal muscle blood flow commonly observed in the elderly (7, 16, 17, 23, 25, 37). 
While there are many regulatory pathways that collectively contribute to the age-related 
decline in limb blood flow, the effects of the alpha-adrenergic and renin-angiotensin-
aldosterone system (RAAS) are of particular interest. Specifically, there is evidence that 
alpha-adrenergic blockade in old individuals partially restores resting limb blood flow 
towards that of the young (8), suggesting an age-related alteration in this receptor group. 
Though less well studied, there is also evidence to suggest an important role of the RAAS 
pathway; we recently identified a significantly greater vasoconstriction in response to 
angiotensin-II (ANG-II) in the old compared to their young counterparts (37), implicating 
this pathway as an additional, potentially significant contributor to the regulation of 
resting skeletal muscle blood flow in the old.  
While the independent contribution of these two pathways to excessive vascular 
tone in the elderly may be substantial, significant cross-talk exists that could produce 
synergistic behavior between these two pathways. Indeed, circulating ANG-II acts as a 
potent vasoconstrictor not only through binding to ANG-II subtype 1 (AT1)  receptors 
located on the vascular smooth muscle (12), but also through binding to AT1 receptor 
located presynaptically on postganglionic sympathetic nerves and enhancing  the release 
of norepinephrine (NE), attenuating the reuptake of NE, and ultimately potentiating 
alpha-adrenergic vasoconstriction  (5, 18). Considering the evidence for an age-related 
increase in circulating ANG-II and AT1 receptor density (9, 29), the direct and indirect 
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(alpha-adrenergic-mediated) vasoconstricting effects of ANG-II in the elderly may be 
profound. This age-associated increase in RAAS activity is especially
 
important in the 
context of underlying changes in autonomic
 
function with age. Indeed, one of the most 
pronounced and reproducible observations associated with aging is a progressive increase 
in muscle sympathetic nerve activity (MSNA) (6, 20, 31), which is modulated 
peripherally by both the alpha-adrenergic and RAAS pathways. Thus, it follows that in 
the presence of this elevated basal MSNA, the potentiating effect of circulating ANG-II 
may be even more pronounced. Considering this, presynaptic AT1 receptors may be seen 
as uniquely positioned to act as a regulatory point for sympathetic nervous system control 
of skeletal muscle blood flow.  
The degree to which postsynaptic AT1 receptors and the potentiating effects of 
ANG-II on alpha-adrenergic vasoconstriction contribute to the enhanced ANG-II-
mediated vasoconstriction in the elderly is currently unknown. Therefore, this study 
sought to evaluate the functional consequence
 
of age-related changes in ANG-II-
mediated vasoconstriction in the presence and absence of alpha-adrenergic 
vasoconstriction. We hypothesized that ANG-II-mediated
 
vasoconstriction would be 
greater in the old compared to the young,
 








   Eight young (26 ± 1 yrs) and six old (68 ± 3 yrs) healthy subjects were enrolled
 
in this study. All subjects were nonsmokers and were normally active. Subjects were not 
taking any
 





indicated by a health history. Protocol approval and written informed consent were 
obtained
 
according to the University of Utah and the Salt Lake City Veterans Affairs 
(VA) Medical Center Institutional Review Board requirements. All data collection took 
place at the VA Salt Lake City Geriatric, Research, Education, and Clinical Center 
(GRECC) Utah Vascular Research Laboratory (UVRL). Subjects remained supine in a 
thermoneutral environment for the duration of the study. 
 
Protocols 
Subjects reported to the UVRL fasted at 0800 on the experimental
 
day. Catheters 
(18 G, 20 cm, Arrow) were placed in the brachial artery (BA) and basilic or cephalic vein 
using sterile technique, with the site of the BA catheter insertion approximately 10 cm 
distal to the axilla and both catheters advanced 6-8 cm in the proximal direction. The 
arterial catheter was placed in this region of the upper arm to ensure that study drugs 
entered the artery “upstream” (~15 cm) to the ultrasound Doppler sample volume, 
allowing assessment of drug effects on BA diameter and blood velocity (39).  A 
microelectrode was placed in the peroneal nerve for direct assessment of basal muscle 
sympathetic nerve activity (MSNA), as described previously (34). Following catheter and 
microelectrode placement, the drug infusion protocol was performed, as illustrated in 
Figure 2.1.  
 
Study Drugs  
Lower and upper arm volumes were determined anthropometrically, and then 
used for the calculation of drug dosing. Total limb volume receiving infusate was 




Total volume (dl) = forearm volume + (upper arm x 0.5) 
 
A portion of the upper arm was included in this calculation due to the proximal location 
of the arterial catheter.  
Angiotensin-II (ANG-II) (Bachem, Germany) was diluted from 50 µg of 
lypholyzed powder in normal saline (0.9% NaCl) to a concentration of 0.125 µg/ml.  The 
drug was infused intra-arterially at 0.8-1.6-3.2-6.4-12.8 ng/dl/min (3 min each dose). 
Norepinephrine Bitartrate (NE) (Levophed, Hospira, Lake Forest, IL) was diluted from 4 
mg suspension in 5% dextrose to a concentration of 1 µg/ml.  The drug was infused intra-
arterially at 2.5-5-10-20-40 ng/dl/min (3min each dose). If a subject did not exhibit a 
plateau in BA blood flow and BA diameter after the fifth dose of ANG-II or NE, a sixth 
doubling dose (ANG-II, 25.6 ng/dl/min; NE 80 ng/dl/min) was administered of the 
respective drug. Phentolamine Mesylate (PHEN) (Regitine, Bedford Labs, Bedford, OH) 
was diluted from 5 mg lypholyzed powder in normal saline (0.9% NaCl) to a 
concentration of 83.3 µg/ml. The drug was infused at a rate of 10 µg/dl/min for 20 
minutes followed by a maintenance dose 5 µg/ml/dl during the remainder of the protocol. 
In a subset of subjects (n = 4 young, n = 4 old), NE was also infused at 5 and 20 
ng/dl/min (3 min each dose) at the end of the alpha-adrenergic blockade portion of the 














Ultrasound Doppler assessments 
Simultaneous measurements of BA blood velocity
 
and vessel diameter were 
performed in both the infused and control arms using Logiq
 
7 and Logiq e ultrasound 
Doppler systems (GE Medical Systems, Milwaukee, WI) operating in duplex mode. The
 
Logic 7 and Logic e were equipped with linear array transducers
 
operating at imaging 
frequencies of 14 and 12 MHz, respectively. Blood velocity was obtained
 
using the same 
transducers with a Doppler frequency of 5 MHz.
 
All blood velocity measurements were 
obtained with the probe
 
appropriately positioned to maintain an insonation angle of 60° 
or less. The sample volume was maximized according to
 
vessel size and was centered 
within the vessel on the basis
 
of real-time ultrasound visualization. 
 
Brachial artery diameter, blood velocity, and blood flow analyses 
Mean velocity values (Vmean, angle-corrected and intensity-weighted
 
area-under-
the-curve) were calculated using
 
commercially available software (Logic 7 and Logic e). 
End-diastolic, ECG R-wave-gated images were collected via video output from the Logic 
7 and Logic e for off-line analysis of BA vasodilation using automated edge-detection 
software (Medical Imaging Applications, Coralville, Iowa). Using BA
 
diameter and Vmean 









Muscle sympathetic nerve activity assessment 
Basal muscle sympathetic nerve activity (MSNA) was recorded directly from the 
peroneal nerve, as described previously (10, 21, 32). Briefly, a tungsten microelectrode 
was inserted into fascicles of the peroneal nerve near the fibular head of the left leg. 
Neural signals were processed by a preamplifier and amplifier (Nerve traffic analyzer 
model 662C-3, Iowa City, IA) with a total gain of 90,000. Amplified signals were filtered 
(bandwidth, 700–2,000 Hz), rectified, and integrated (time constant, 0.l s) to obtain mean 
voltage neurograms. 
 
Arterial blood pressure and heart rate assessment  
Heart rate was monitored
 
from a standard three-lead ECG. Arterial blood pressure 
was acquired continually
 
from within the BA, with the pressure transducer
 
placed at the 
level of the catheter (Transpac IV, Abbot Laboratories).  
 
Blood chemistry   
A lipid panel was performed in all subjects by standard technique. In a subset of  
subjects (n = 6 young, n = 5 old), resting blood samples were obtained from the brachial 
artery and the basilic or cephalic vein. Plasma ANG-II concentration was assessed by 
radioimmunoassay (Bachem, Bubendorf Switzerland), and plasma NE concentration by 
enzyme immunoassay (2-CAT Elisa, Labor Diagnostika Nord, Nordham Germany).  
 
Data analysis  
Ultrasound images and Doppler velocity spectra were recorded
 
continuously. 
During the last 60 s of each ultrasound Doppler segment,
 
Vmean was averaged across five 
12 s intervals, which were matched with intima-to-intima
 
BA diameter measurements 
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evaluated during diastole. Maximal reductions in BA blood flow and BA diameter during 
ANG-II and NE infusions were identified on an individual basis from the three highest 
doses of ANG II (6.4-12.8 25.6 ng/dl/min) and NE (20-40-80 ng/dl/min). Mean arterial 
pressure was calculated using the
 
time integral of the arterial waveform. MSNA bursts 
were was identified according to appearance and timing in relation to the preceding R-
wave, and expressed as burst frequency (bursts per minute). 
The rate of NE spillover into plasma was determined using the following 
equation:  
 
NE spillover (pg/min) = [(Cv – Ca) + Ca (Ee)] ∙ BA blood flow 
 
where Cv and Ca are plasma concentrations of NE (pg/ml) in the basilic or cephalic vein 
and brachial artery (respectively) and Ee is the fractional extraction of epinephrine (27).  
 
Statistical Analyses 
Statistical analyses were performed with the use of commercially available
 
software (SigmaStat 3.10, Systat Software, Point Richmond, CA). Multiple 2x6 mixed 
repeated-measures analysis of variance (ANOVA) were used to identify significant 
changes
 
in measured variables within and between drug conditions, as well between 
young and old. Multiple 2x2 mixed repeated measures ANOVA were used to identify 
significant maximal changes in measured variable between during conditions, as well as 
between young and old. When a significant main effect was found (p < 0.05), the Holm-
Sidak method was used for alpha adjustment and post hoc analysis. Student's t-tests were 
used to identify significant differences in subject characteristics between young and old. 
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Significance for subject characteristics was established
 
at =0.05. All group data are 
expressed as mean ± standard error. 
Results 
Subject Characteristics 
Subject characteristics are presented in Table 2.1.  Resting muscle sympathetic 
nerve activity (MSNA) measurements were attempted in all subjects, and an acceptable 
recording site was identified in 9 of the 14 subjects (n = 3 young, n = 6 old). The old 
exhibited significantly higher resting levels of MSNA, plasma norepinephrine (NE), and 
NE spillover. Plasma ANG-II was similar between young and old (Table 2.2). 
Angiotensin II (ANG-II)   
The overall hemodynamic response to ANG-II was a dose-dependent reduction in 
brachial artery (BA) blood flow (Figure 2.2A, Table 2.2) and diameter (Figure 2.3A, 
Table 2.2), with an apparent plateau in vasoconstriction in both groups. Due to individual 
variability in maximal response to the drug, not all subjects received the same number of 
doses. All subjects received the first 4 doses (0.8-1.6-3.2-6.4 ng/dl/min), 11 of 14 
subjects (n =6 young, n = 5 old) received the fifth dose (12.8 ng/dl/min), and 4 of the 14 
subjects (n = 1 young, n = 3 old) required a sixth dose (25.6 ng/dl/min) to reach maximal 
vasoconstriction. This maximal reduction in BA blood flow identified during doses 4-6 
(6.4-12.8-25.6 ng/dl/min) was significantly greater in the old compared to the young 
(Figure 2.2B).  
  Throughout the dose-response protocol, heart rate (HR), mean arterial pressure 
(MAP), and BA blood flow in the contra-lateral arm were unchanged (Table 2.2), 




During the NE dose-response, significant age-independent reductions in BA blood 
flow and BA diameter were observed (Table 2.3). As with ANG-II, due to individual 
variability in maximal response to the drug, not all subjects received the same number of 
doses of NE. All subjects received the first 4 doses (2.5-5-10-20 ng/dl/min), 11 of the 14 
subjects (n =7 young, n = 4 old) received the fifth dose (40 ng/dl/min), and 10 of the 14 
subjects (n = 7 young, n = 3 old), required a sixth dose (40 ng/dl/min). The maximal 
reduction BA blood flow identified during doses 4-6 (20-40-80 ng/dl/min) was similar 
between young and old (Figure 2.2B). As with ANG-II, HR, MAP, and BA blood flow in 
the contra-lateral arm were unchanged during NE infusion (Table 2.3), confirming that 
the drug remained localized in the vasculature of the infused arm.  
ANG-II during Nonspecific Alpha-Adrenergic Antagonism 
Alpha-adrenergic-receptor blockade by a continuous infusion of phentolamine 
(PHEN) induced a significant age-independent increase in blood flow (young, 149 ± 
39ml/min, P<0.05; old, 182 ± 47ml/min; P<0.05).  NE was administered (5 and 20 
ng/dl/min) at the end of the PHEN infusion (n = 8) to confirm alpha-adrenergic receptor 
blockade. Neither NE dose produced a significant change in BA blood flow (253 ± 92 
ml/min, baseline; 241 ± 29 ml/min, NE 5 ng/dl/min; 223 ± 3 ml/min, NE 20 ng/dl/min).    
Similar to ANG-II alone, the overall response to ANG-II during PHEN was a 
dose-dependent reduction in brachial artery (BA) blood flow in both groups, with an 
attenuated magnitude of change in blood flow in response to ANG-II at the higher doses 
in both groups (Figure 2.2A, Table 2.3). Compared to the ANG-II alone trial, the 
maximal reduction in BA blood flow during ANG-II + PHEN was similar in the young 
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group, but was attenuated in the old (Figure 2.2B, Table 2.3), effectively abolishing the 
age-related differences in ANG-II-mediated vasoconstriction observed during ANG-II 
alone (Figure 2.2B, Table 2.3).  
Brachial Artery (BA) Diameter 
 BA diameter was reduced in the young (doses: 6.4 and 12.8 ng/dl/min) and in the 
old (doses: 6.4 and 12.8 ng/dl/min) (Figure 2.3A). Similar levels of vasoconstriction of 
the BA were induced by ANG-II alone and NE (Figure 2.3B) in both the young (ANG-II:  
-0.57±0.11mm; NE: -0.51 ± 0.19mm) and the old (ANG-II: -0.50 ± 0.13mm; NE: -0.68 ± 
0.06mm). In the presence of alpha-adrenergic receptor antagonism, the ANG-II-mediated 
vasoconstriction of the BA induced by ANG-II was ablated in both the young (ANG-
II+PHEN: -0.06 ± 0.03mm; P<0.05) and the old (ANG-II+PHEN: 0.00 ± 0.02mm; 
P<0.05) (Figure 2.3B). 
 
Discussion 
To better understand the mechanisms regulating the peripheral circulation with 
advancing age, this study sought to examine the interaction between the alpha-adrenergic 
and renin-angiotensin-aldosterone (RAAS) systems. A significant increase in sympathetic 
nervous system (SNS) activity was observed in the elderly, which was accompanied by 
an age-related increase in brachial artery (BA) vasoconstriction in response to intra-
arterial angiotensin-II (ANG-II) administration. Following alpha adrenergic blockade, 
ANG-II-mediated vasoconstriction was restored to that of the young. These data reveal 
that with healthy aging, an increased ANG-II receptor sensitivity may be attributed in 
part to a potentiation of alpha-adrenergic vasoconstriction, and implicate the “cross-talk” 
between the RAAS and adrenergic systems as an important consideration in therapeutic 
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strategies targeting these two pathways. In the context of an age-related increase in SNS 
activity, these findings may also represent a potential mechanism contributing to 
enhanced alpha-adrenergic-mediated vascular tone associated with healthy aging. 
 
ANG-II and Blood Flow Regulation with Age 
  This study has identified an enhanced dose-dependent as well as maximal 
reduction in BA blood flow to intra-arterial infusion of ANG-II in healthy old individuals 
compared to their young counterparts (Figure 2.2, Table 2.2).  These findings are in 
agreement with previous work from our group, identifying a greater reduction in leg 
blood flow in old individuals compared to the young following femoral artery ANG-II 
infusion (37). Through the inclusion of an ANG-II dose response protocol (Figures 2.1 
and 2.2), the assessment of  circulating ANG-II, and control limb measurements, this 
study expands on this previous work, confirming the apparent increase in ANG-II 
mediated reduction in blood flow in healthy, old adults. 
This  enhanced reduction in blood flow induced by exogenous ANG-II in the old 
contrasts with the work of Hogikyan and Supiano (13), who observed a similar change in 
forearm blood flow in old and young individuals in response to brachial artery (BA) 
infusion of ANG-II. This discrepancy may be, in part, due to the differences in 
methodology and drug dosing. The aforementioned study (13) used venous occlusion 
plethysmography to measure forearm blood flow and  administered a dose of ANG-II that 
elicited a systemic pressor response.  In contrast, in the present study ultrasound Doppler 
was utilized to determine BA blood flow, there was no significant change in mean arterial 
pressure (MAP), and BA blood flow in the contra-lateral (noninfused) arm during intra-
arterial infusion of ANG-II was documented to be unchanged (Table 2.2). Therefore, 
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through a controlled and comprehensive experimental design, the present findings build 
on previous observations, and now identifying a clear that the ANG-II-mediated 
reduction in blood flow is enhanced in the elderly.  
ANG-II Dose-Response during Alpha-Adrenergic Antagonism and Age 
ANG-II acts as a potent vasoconstrictor not only through binding to ANG-II 
subtype 1  (AT1)  receptors located on the vascular smooth muscle (12), but also by 
potentiating alpha-adrenergic vasoconstriction (5, 18). Thus, recognizing the enhanced 
reduction in blood flow induced by ANG-II with age (37) (Figure 2.2), we sought to 
evaluate the potential impact of age on AT1 receptors located presynaptically on 
postganglionic sympathetic nerves, as this receptor group is known to potentiate the 
release and inhibit the reuptake of NE (5, 30).  
To pharmacologically probe the role of these presynaptic AT1 receptors, we 
repeated the ANG-II dose response protocol with concomitant infusion of the 
nonselective alpha-adrenergic receptor antagonist PHEN. In support of our hypothesis, 
the age-associated increase in the ANG-II-mediated reduction in blood flow was 
abolished after alpha-adrenergic blockade, such that the maximal reduction in blood flow 
in response to ANG-II was similar to that observed in the young group (Figure 2.2B). 
These data thus indicate that alpha-adrenergic vasoconstriction is responsible for nearly 
20% of the maximal reduction in blood flow induced by intra-arterial ANG-II infusion in 
the old (Figure 2.2B), approximately double that observed in the young (10%).   
The interaction between the RAAS and alpha-adrenergic pathways in the 
peripheral circulation of young, healthy subjects is well documented. Both Seidelin et al. 
(28) and Webb et al. (33) observed that BA infusions of  low-doses of ANG-II (at 
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concentrations that do not effect forearm blood flow) enhanced the  sympathetically-
mediated reduction in blood flow induced by lower body negative pressure. Importantly, 
when NE and ANG-II were infused concomitantly in these studies, no potentiating effect 
of ANG-II was evident, providing evidence in support of presynaptic AT1 receptors as 
the site of action. Using higher doses of ANG-II, Lyons et al. (18) demonstrated a 
marked reduction in blood flow in response to intra-arterial ANG-II in the young that was 
significantly reduced (~36%) in the presence of PHEN. However, the use of significantly 
higher doses of ANG-II and the lack of blood pressure measurements in the former study 
limits a direct comparison with the present findings. Specifically, the present study 
extends the evidence for an alpha receptor-mediated contribution to the vasoconstrictor 
action of ANG-II in the young, and an enhanced synergistic interaction between ANG-II 
and the alpha-adrenergic system which contributes to the age-associated increase in the 
ANG-II-mediated reduction in blood flow. 
AT1 and Alpha-Adrenergic Receptor Distribution  
By design, all study drugs were infused into the BA proximal to where the vessel 
was imaged, allowing the unique opportunity to assess BA diameter changes in response 
to ANG-II, PHEN, and NE. Independent of age, ANG-II produced a dose-dependent 
vasoconstriction of the BA diameter (Figure 2.3A, Table 2.2), which initially was thought 
to provide evidence for AT1 receptors in the BA. However, during co-infusion with 
PHEN, ANG-II administration did not change BA caliber (Figure 2.3), indicating that 
ANG-II-mediated vasoconstriction of the BA was, in fact, achieved through the alpha-
adrenergic pathway. The alpha-adrenergic dependence of this response is further 
supported by the similar maximal reductions in BA diameter induced by ANG-II and NE 
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(Figure 2.3B). Thus, it seems AT1 receptors may be distributed heterogeneously 
throughout the arterial tree. Specifically, AT1 receptors located on vascular smooth 
muscle appear to be located distal to the BA, while those located presynapticlly on 
sympathetic-adrenergic nerves may be located in both the proximal and distal portions of 
the arm vasculature.  
The ANG-II-mediated vasoconstriction of the BA documented in this study is in 
contrast with earlier studies from our group performed in the leg. Specifically, we 
previously observed minimal changes in the diameter of the common femoral artery 
(CFA) diameter in response to ANG-II infusion (3, 37), while the alpha-1 adrenergic 
agonist phenylephrine provoked a significant reduction in CFA caliber  (3, 35, 36, 38). 
The explanation for this disparity is most likely related to limb differences. Studies that 
have utilized reflex increases in muscle sympathetic nerve activity (MSNA) have 
observed sympathetically-mediated vasoconstriction of the BA (1), while the leg does not 
appear to have significant sympathetic innervation at the level of the CFA (14, 15, 24), 
despite the presence of alpha-1-adrenergic receptors in this large conduit vessel (3, 35, 
36, 38). Together, the prior and  current data indicate that the age-independent ANG-II 
potentiation of alpha-adrenergic vasoconstriction may be limited to those alpha receptors 
that are sympathetically innervated, and thus support a presynaptic site of action for this 
potentiating effect of ANG-II and the RAAS on the alpha-adrenergic system, as reported 
previously (28, 33). 
Perspectives 
To our knowledge, this is the first study to demonstrate that a significant part of 
the vasoconstrictive action of ANG-II in the old is mediated through the alpha-adrenergic 
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system, which may have important implications for the regulation of skeletal muscle 
blood flow in this population. Indeed, healthy aging is associated with a concomitant rise 
in MSNA (6, 31) (Table 2.1) and a reduction in skeletal muscle blood flow (7, 16, 17), 
and it has been suggested that upwards of 80% of the age-associated reduction in skeletal 
muscle blood flow can be explained by the alpha-adrenergically-mediated contribution to 
vascular tone (8). In this light, the potentiating effects of ANG-II on NE release and 
alpha-adrenergic vasoconstriction with age may not only indicate an important site of 
ANG-II modulation of sympathetic-adrenergic vasoconstriction, but also a potential 
mechanism contributing to enhanced alpha-adrenergic-mediated vascular tone associated 
with healthy aging.  
The interaction between the RAAS and sympathetic-adrenergic system may be of 
particular relevance in cardiovascular disease states characterized by an elevation in 
activity of these two respective systems, such as hypertension and heart failure (2, 11). 
Indeed, recognition of the current underlying contribution of alpha-adrenergic 
vasoconstriction to ANG-II-mediated vasoconstriction in the elderly may be an important 
mechanism by which hypertension develops with advancing age. This concept is 
predicated on the observed efficacy of the AT1 receptor blockade in reducing resting 
blood pressure (4), vascular compliance (26),  and vascular tone (19) in hypertensive 
patients. These functional vascular changes that are potentially due to the ability to block 
the presynaptic AT1 receptor, limiting NE release (22). Thus, we speculate that the 
present data, identifying an apparent enhanced contribution of alpha-adrenergic 
vasoconstriction to ANG-II-mediated vasoconstriction with age, may represent one 




This study has identified an enhanced in ANG-II-mediated reduction in limb 
blood flow in healthy older individuals, and demonstrated that this apparent increase in 
sensitivity to ANG-II is due, at least in part, to an ANG-II-mediated potentiation of 
alpha-adrenergic vasoconstriction. These findings suggest that cross-talk between the 
RAAS and adrenergic systems may be an important regulator of resting vascular tone and 
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FIGURE 2.1: Protocol Timeline. 5 doubling doses of Angiotensin-II (ANG-II) and 
norepinephrine (NE) were administered (3 min per dose), with the goal of a “saturating 
dose” that produced maximal local receptor occupancy. If deemed necessary, a sixth 
doubling dose of ANG-II (25.6 ng/dl/min) or NE (80 ng/dl/min) was given in order to 
induce maximal changes in BA blood flow and BA diameter. The order of ANG-II and 
NE administration was balanced, but the remainder of the protocol was ordered due to 






































FIGURE 2.2 A: Changes in brachial artery (BA) blood flow in young (circles) and  old 
(triangles) subjects during continuous infusion of angiotensin-II (ANG-II) before (filled 
symbols), and after (open symbols) alpha-adrenergic blockade with phentolamine 
(PHEN). B: Maximal reductions in BA blood flow induced by norepinephrine (NE), 
ANG-II alone, and ANG-II after nonselective alpha-adrenergic blockade with PHEN. 
The reduction in BA blood flow in response to NE (black bars) was similar in both 
groups. The ANG-II (light grey bars) - mediated reduction in BA blood flow was 
significantly greater in old compared to young subjects, and this age-related response to 
ANG-II was ablated in the presence of alpha-adrenergic blockade (dark grey bars). 
*Significantly different then baseline in both you and old.  ‡Significantly different from 
PHEN in both young and old. # Significantly different from ANG-II alone in both young 
and old. ## Significantly different from ANG-II alone in the old. † Significantly different 
from young, P<0.05.  









FIGURE 2.3 A: Changes in brachial artery (BA) diameter in young (circles) and old 
(triangles) subjects during continuous infusion of angiotensin-II (ANG-II) alone (filled 
symbols), and ANG-II with concomitant alpha-adrenergic blockade with phentolamine 
(PHEN) (open symbols).  B: Maximal reductions in BA diameter induced by 
Norepinephrine (NE), ANG-II alone, and ANG-II with concomitant alpha-adrenergic 
blockade via PHEN.  Diameter changes in response to NE (black bars) and ANG-II (light 
gray bars) were similar in both groups, while BA diameter was virtually unchanged in the 
presence of alpha-adrenergic blockade (dark grey bars). * Significantly different from 
baseline in both you and old.  # Significantly different from ANG II alone in young and 

















Table 2.1. Subject characteristics        
  
 YOUNG                    OLD 
  
      












































































Plasma ANG-II (arterial pg/ml) (n = 10)   64.2±8.7   58±12.7   
 
ANG-II, Angiotensin-II; HDL, high density lipoprotein; LDL, low density lipoprotein; 
MSNA, muscle sympathetic nerve activity; NE, norepinephrine. Values are mean ± SE. † 




































TAMING THE “SLEEPING GIANT”: THE ROLE OF ENDOTHELIN-1 IN THE 
REGULATION OF SKELETAL MUSCLE BLOOD FLOW AND  




















The degree to which endogenous ET-1 participates in the regulation of skeletal 
muscle vascular tone and arterial blood pressure during dynamic exercise is largely 
unknown. Thus, in eight young (24±2 yrs), healthy volunteers, we examined changes in 
common femoral artery (CFA) blood flow (ultrasound Doppler), mean CFA blood 
pressure, heart rate, leg a-vO2 difference, leg VO2, pH, and net ET-1 and lactate release at 
rest and during knee extensor exercise (0-5-10-15-20-30W) before and after endothelin 
receptor subtype A (ETA) blockade (intra-arterial BQ-123, 10 nmol/min/liter of thigh 
volume). At rest, BQ-123 evoked no change in CFA blood flow or blood pressure. 
During exercise, net ET-1 release across the exercising leg increased ~3-fold. BQ-123 
increased CFA blood flow by ~20% (113 ± 76, 176 ± 83, 304 ± 108, 364 ± 130, 502 ± 
117, and 570 ± 178 ml/min at 0-5-10-15-20-30W, respectively) and attenuated the 
exercise-induced increase in mean CFA blood pressure by ~6% (-3 ± 3, -3 ± 2, -6 ± 3, -7 
± 1, -8 ± 1, -9  ± 3 mmHg at 0-5-10-15-20-30W, respectively) in an intensity-dependent 
manner. The increase in CFA blood flow was accompanied by a ~9% increase in leg VO2 
with unchanged a-vO2, suggesting a reduced efficiency of the active muscle following 
ETA receptor blockade. Together, these findings have identified a significant role of the 
ET-1 pathway in the cardiovascular response to exercise, implicating vasoconstriction via 
the ETA receptor as an important mechanism for both restraint of blood flow in the 







During dynamic exercise of increasing intensity, oxygen demand of the exercising 
muscle is dramatically elevated, requiring a marked increase in skeletal muscle blood 
flow that is accomplished through a combination of systemic sympathoexcitation and 
local metabolic vasodilation (22). Sympathetic activation acts both centrally and 
peripherally, increasing cardiac output and inducing vasoconstriction of the internal 
organs and less active skeletal muscle in order to redistribute blood flow to more active 
tissue (7, 45, 47). However, in the face of local metabolic byproducts produced by the 
exercising muscle, the sympathetic vasoconstrictor stimulus appears less effective, a 
phenomenon termed “functional sympatholysis” (41). In combination with regional 
vasodilatory influences, this reduction in overall vasoconstrictor “efficacy” evokes a 
requisite increase in limb blood flow and vascular conductance within the exercising limb 
to ensure adequate delivery of oxygen to the exercising tissue. 
While vasodilation of active skeletal muscle is an essential component in the 
cardiovascular response to exercise, it must be balanced with the concomitant need to 
support arterial blood pressure. Indeed, leg blood flow values as high as 4 L/kg/min have 
been observed during small muscle mass exercise (42), suggesting that the skeletal 
muscle represents a “sleeping giant” that must be under tonic restraint to avoid 
hypotension during intense, whole-body exercise (46). Studies utilizing isolated arm and 
leg exercise modalities support this concept, demonstrating a reduction in arterial blood 
pressure when additional muscle mass is recruited at near maximal exercise intensities, 
even in the face of drastic increases in sympathetic nervous system activity (10, 42, 50, 
55). From these observations, the concept has emerged that exercise-induced metabolic 
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vasodilation must be restrained to some degree in order to protect against precipitous 
drops in arterial blood pressure as the limit of cardiac output is reached. Though a small 
number of studies have documented some degree of sympathetic restraint within the 
exercising limb (19, 37), the preponderance of data from studies in both animals and 
humans have demonstrated substantial blunting of sympathetic vasoconstriction in the 
exercising skeletal muscle vasculature (9, 11, 44, 48, 52, 56). In the face of this intensity-
dependent loss of regional sympathetic control, it is likely that nonadrenergic 
vasoconstrictor pathways may contribute importantly to the balance of skeletal muscle 
blood flow and arterial blood pressure during exercise.  
One such vasoconstrictor that may be relevant in this regard is Endothelin-1 (ET-
1), the most potent endogenous vasoconstrictor (61). In the periphery, ET-1 provokes a 
sustained vasoconstrictor response by binding to endothelin subtype A (ETA) and B 
(ETB) receptors located primarily on the vascular smooth muscle (4, 61). This 
endothelial-derived peptide is released in response to a variety of stimuli, including 
increases in pulsatile stretch (26), shear stress (31), hypoxia (21), and a reduction in pH. 
Since these physical and chemical stimuli are among the host of changes that take place 
within the skeletal muscle during exercise (25), ET-1 has been implicated as an important 
signaling molecule in the response to exercise. Indeed, circulating concentrations of ET-1 
have been documented to increase in an intensity-dependent manner during exercise (28), 
suggesting a potential role of ET-1 in blood flow distribution and the support of arterial 
blood pressure. Previous work in animals has evaluated the tonic ET-1-mediated restraint 
on vascular tone via ETA and concomitant ETA/ETB receptor blockade during exercise, 
and reported that ETA receptor inhibition improved exercising muscle blood flow (35). 
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Recently, our group identified an attenuated vasoconstriction in response to intra-arterial 
infusion of ET-1 during dynamic knee-extensor exercise in young, healthy humans (57). 
However, the role of endogenous ET-1, specifically the ETA receptor, in the regulation of 
exercising limb blood flow and arterial blood pressure has yet to be investigated.  
Therefore, the current study sought to determine the endogenous contribution of 
the ETA receptor in the regulation of blood flow and arterial blood pressure during 
dynamic exercise of increasing exercise intensities. We hypothesized that: 1) intra-
arterial, local ETA receptor blockade would enhance exercising skeletal muscle blood 
flow in an intensity-dependent manner;  and 2) The reduction in vascular tone induced by 
ETA receptor blockade would attenuate the increase in arterial blood pressure present 




Subjects   
Eight young (24 ± 2 yrs), healthy subjects were enrolled
 
in the present study. All 
subjects were nonsmokers and were normally active. Subjects were not taking any
 
prescription medication and were free of overt cardiovascular
 
disease, as indicated by a 
health history. Protocol approval and written informed consent were obtained
 
according 
to the University of Utah and the Salt Lake City Veterans Affairs (VA) Medical Center 
Institutional Review Board requirements. All data collection took place at the VA Salt 
Lake City Geriatric, Research, Education, and Clinical Center (GRECC) in the Utah 






Subjects reported to the UVRL at 0800 on the experimental day. After 30 min of 
supine rest, two catheters (common femoral artery (CFA) and femoral vein) were placed 
using sterile technique, as previously reported  (1, 5, 60). After catheter placement, 
subjects rested for ~30 min, and then underwent the protocol as outlined in Figure 3.1. 
Due to the duration of the study, subjects were given 1/2 cup of corn flakes and 1/2 cup 
of skim milk before the start of the control (saline) and BQ-123 trials to prevent 
hypoglycemia (Figure 3.1). All data collection took place with subjects in a 
semirecumbent position (60° reclined), and all studies were performed in a thermoneutral 
environment.  
Due to the long lasting effects of BQ-123, the drug administration portion of the 
protocol always occurred after the saline portion of the protocol. Thus, to minimize the 
risk that the observed changes in CFA blood flow and arterial blood pressure were the 
consequence of an exercise ordering effect, rather than the effect of the drug per se, 
subjects returned to the laboratory on a separate day to undergo an exercise time control 
study. For this visit, catheters were not placed, and no drugs were administered. Apart 
from these differences, the timeline for this study was identical to the drug infusion day, 
with the addition of leg blood flow measurements immediately before and after a light 
meal to examine possible postprandial hemodynamic effects.  
 
Drug Infusions  
Thigh volumes were determined anthropometrically, and then used for the 
calculation of drug dosing. A selective ETA receptor antagonist (BQ-123 Clinalfa, 
49 
 
Calbiochem-Novabiochem, La¨ufelﬁngen, Switzerland) was prepared in normal saline 
(0.9% NaCl) and administered intra-arterially (CFA) at 10 nmol/min/liter of thigh volume 
(infusion rates 0.8-1.5 ml/min). This dose has been documented to induce an apparent 
plateau in vasodilation in both the forearm (13, 16) and quadriceps (51), without affecting 
arterial blood pressure. BQ-123 has been documented to have a high affinity for the ETA 
receptor (17) and effectively counteracts the vasoconstrictor effect of ET-1 infusion in the 
human forearm (15). During the control trial, normal saline (0.9% NaCl) was 
administered intra-arterially into the CFA at the same infusion rates as BQ-123. 
 
Exercise Model 
The knee extensor (KE) paradigm implemented in this study has been described 
previously (2, 23, 43, 59). Briefly, subjects were seated on an adjustable chair with a 
cycle ergometer (model 828E; Monark Exercise AB, Vansbro, Sweden) positioned 
behind them. Resistance was created by applying friction to the flywheel, which was 
turned by the subject via a metal bar that connects the crank arm of the ergometer and the 
subject’s foot, which is placed in a metal boot. Sixty contractions per minute were 
maintained at each work rate. Subjects exercised for 3 min at six exercise intensities (0-5-





Ultrasound Doppler assessments 
Measurements of CFA blood velocity
 
and vessel diameter were performed in the 
infused leg using a Logiq
 
7 ultrasound Doppler system (GE Medical Systems, 
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Milwaukee, WI) operating in duplex mode. The
 
Logic 7 was equipped with a linear array 
transducer
 
operating at an imaging frequency of 14 MHz. The CFA was insonated 2-3 cm 
proximal to the bifurcation of the CFA into the superficial and deep branches. The blood 
velocity profile was obtained
 
using the same transducer with a Doppler frequency of 5 
MHz, operated in the high-pulsed repetition frequency mode (2-25 kHz). Care was taken 
to avoid aliasing the blood velocity spectra by using scale adjustments, especially during 
exercise.
 
All blood velocity measurements were obtained with the probe
 
appropriately 
positioned to maintain an insonation angle of
 
60° or less (24). The sample volume was 
maximized according to
 
vessel size and was centered within the vessel on the basis
 
of 
real-time ultrasound visualization.  
 
Common femoral artery diameter, blood velocity, and blood flow analyses 
At all sample points, arterial diameter (cm) and angle-corrected, time-averaged, 
and intensity-weighted mean blood velocity (Vmean) values were calculated using
 
commercially available software (Logic 7). Using measured
 
arterial diameter and Vmean, 
CFA blood flow was calculated according to the equation: 
 
CFA blood flow (ml/min) = (Vmean × π (vessel diameter/2)
2
 × 60) 
 
Arterial blood pressure, vascular conductance, and heart rate assessment 
Arterial blood pressure measurements were collected continuously from the 
indwelling catheter placed in CFA with the pressure transducer placed at the level of the 
catheter (Transpac IV, Abbott Laboratories).  Mean CFA blood pressure (mmHg) was 
calculated as diastolic arterial pressure + (arterial pulse pressure x 0.33). On the time 
control study day, mean arterial blood pressure was determined noninvasively using 
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finger photoplethysmography (Finometer, Finapres Medical Systems BV, Amsterdam, 
The Netherlands). CFA vascular conductance was calculated as CFA blood flow / mean 
CFA blood pressure.  Heart rate was monitored from a standard three-lead ECG recorded 
in duplicate on the data acquisition device (BIOPAC U.S.A.) and the Logic 7. 
 
Blood chemistry 
A lipid panel was obtained for all subjects by standard techniques. At each 
exercise intensity, samples (3-4 ml) of femoral arterial and venous blood were collected. 
1 ml of arterial and venous blood were presented anaerobically to a GEM 4000 blood-gas 
analyzer and co-oximeter (Instrumentation Laboratories, Bedford, MA) to obtain arterial 
and venous total hemoglobin (tHb) oxyhemoglobin saturation (SO2), partial pressure of 
oxygen (PO2), hematocrit (hct), lactate, and pH. Blood oxygen content (CO2) (ml/dl) was 
calculated as: 
 
Blood oxygen content (ml/dl) = 1.39 (tHb) × (SO2/100) + 0.003 × PO2 
 
 Leg oxygen consumption (VO2) (ml/min) was calculated as: 
  
Leg oxygen consumption (ml/min) = (CaO2 − CvO2) × CFA blood flow 
 
where CaO2 and CvO2 represent arterial and venous oxygen content. The remaining blood 
was spun down for plasma samples, and stored at -80°C until analysis.  
Plasma ET-1 concentrations were evaluated via sandwich radioimmunoassay 
(Stressgen Bioreagents). Using arterial (CA) and venous (CV) plasma ET-1 or lactate 
concentrations, with corrections for hematocrit (hct) and CFA blood flow, “net ET-1 
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release” and “net lactate release” were calculated (18, 53)  according to the following 
equation:   
 
 Net ET-1 or lactate release = (CV – CA) × (CFA blood flow × ((101 – (hct/100)) 
 
Statistical Analyses 
Statistics were performed with the use of commercially available software 
(SigmaStat 3.10; Systat Software, Point Richmond, CA). Multiple 2x7 repeated measures 
analysis of variance (ANOVA) were used to identify significant changes in measured 
variables within and between drug groups and across exercise intensities. Multiple 1x7 
repeated measures ANOVA were used to identify significant changes in BQ-123-induced 
changes. When a significant main effect was found (p < 0.05), the Holm-Sidak method 
was used for alpha adjustment and post hoc analysis. All group data are expressed as 




Subject Characteristics  
Subject characteristics are presented in Table 3.1. 
BQ-123 at Rest and Exercise  
Endothelin subtype A (ETA) receptor inhibition BQ-123 was infused continuously 
(10 nmol/min/liter of thigh volume; infusion rate 0.8-1.5 ml/min) for 45 min. This intra-
arterial infusion did not significantly change heart rate (Table 3.2), mean CFA blood 
pressure, CFA blood flow, CFA vascular conductance, leg VO2, Leg a-vO2diff, pH, net 
lactate release, or net ET-1 release (Figures 3.2, 3.3, and Table 3.2).  During exercise, 
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BQ-123 induced a significant intensity-dependent increase in CFA blood flow and 
vascular conductance (Figures 3.2 and 3.3), accompanied by an intensity-dependent 
reduction in mean CFA blood pressure (Figures 3.2 and 3.3) and no change in heart rate 
(Table 3.2) compared to the saline trial. The vasodilation provoked by BQ-123 during 
exercise led to an increase in leg VO2 (Table 3.2) without an alteration in leg a-vO2diff 
(Table 3.2). Additionally, a significant increase in the net ET-1 release and no significant 
changes in net lactate release or pH were observed during BQ-123 infusion during 
exercise compared to the saline trial (Table 3.2). 
 
Exercise Time Control Study  
All eight subjects who participated in the drug infusion protocol returned to the 
lab for an exercise time control protocol. This additional protocol allowed for the 
assessment of CFA blood flow and mean arterial blood pressure during multiple exercise 
bouts and the consequence of food consumption without the influence of catheter 
insertion and drug infusions. Measurements were highly reproducible, with no significant 
difference in CFA blood flow or mean arterial blood pressure between the two exercise 
bouts (Figure 3.4). 
 
Discussion 
There are several key findings from the present study. During small muscle mass 
(knee-extensor) exercise, common femoral artery (CFA) blood flow and vascular 
conductance were significantly elevated in the exercising limb following ETA receptor 
inhibition, demonstrating a substantial (~20%) ETA-mediated restraint of skeletal muscle 
blood flow at the higher exercise intensities. ETA blockade also blunted the intensity-
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dependent rise in arterial blood pressure produced during exercise, suggesting that the 
ET-1 pathway may also play an important role in the support of blood pressure. The 
increase in CFA blood flow following BQ-123 was accompanied by an increase in leg 
VO2 with no change in a-vO2, effectively decreasing intramuscular efficiency. A 
significant rise in net ET-1 release across the exercising leg in an intensity-dependent 
manner was also observed. Collectively, these findings have identified a significant role 
of the ET-1 pathway in the cardiovascular response to exercise, implicating 
vasoconstriction via the ETA receptor as an important mechanism for both restraint of 
blood flow in the exercising limb and support of arterial blood pressure in healthy, young 
adults.  
 
ETA Receptor Antagonism during Exercise  
With increasing exercise intensity, one of the principle ways in which skeletal 
muscle blood flow is elevated to meet the metabolic demands of the exercising muscle is 
through the reduction of vascular tone in the vascular beds perfusing the exercising 
muscle. Indeed, the attenuated ability of infused sympathomimetics to evoke 
vasoconstriction during exercise in an intensity-dependent manner provides evidence that 
sympathetic vasoconstrictor pathways are at least partially inhibited during exercise (8, 
11, 52, 56, 57). However, this increase in skeletal muscle blood flow must be balanced by 
the concomitant need to support arterial blood pressure (45). With the knowledge that 
ET-1 provokes a sustained vasoconstriction (14, 35) and circulating levels increase 
during exercise (28), we sought to evaluate the putative role of the endothelin subtype A 
(ETA) receptors in the regulation of skeletal muscle blood flow and maintenance of 
arterial blood pressure in the exercising limb vasculature during bouts of exercise of 
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increasing intensity. Results indicate that the ET-1 vasoconstrictor pathway plays an 
important role in the regulation of limb blood flow, arterial blood pressure, and 
intramuscular efficiency as discussed below.   
In support of our first hypothesis, we observed a progressively greater BQ-123-
induced increase in CFA blood flow with increasing exercise intensity (Figure 3.3). This 
observed response is  in contrast to that of McEniery et al. (34), who examined the effect 
of ETA receptor blockade on limb blood flow during 15 min of static intermittent 
handgrip exercise in hypertensive and normotensive individuals. This study reported no 
difference in forearm blood flow during exercise between the blocked and control trials 
in the normotensive group, suggesting no apparent role of the ETA receptor in the 
regulation of vascular tone during handgrip exercise. This discrepancy between the 
current study and that of McEniery et al. may be partially attributable to the differences 
in limbs that were exercised. First, our group (58) and others (40) have identified 
substantial differences in the regulation of blood flow between the arms and legs and this 
limb specificity might explain the differing responses to ETA receptor blockade between 
the former and present studies. Additionally, in this previous study (34), the vascular beds 
perfusing the forearm may not vasodilate to a degree in which the maintenance of arterial 
blood pressure is challenged.  The use of the knee-extensor exercise paradigm in the 
present study allowed for the quadriceps muscle to be exercised, a large postural muscle-
group with a vasodilatory capacity large enough to challenge the maintenance of arterial 
blood pressure. With this approach, we have identified for the first time a functional role 
of the ET-1 pathway in the regulation of exercise muscle blood flow in the large, 
ambulatory muscle groups of the leg. 
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In addition to restraint of muscle blood flow, ETA receptor-mediated maintenance 
of vascular tone in the exercising skeletal muscle vasculature also appears to play a 
significant role in the support of arterial blood pressure. Indeed, we observed an overall 
reduction in the “exercise pressor” response (36) following ETA receptor blockade 
(Figure 3.2). Interestingly, this hypotensive effect was intensity-dependent (Figure 3.3), 
indicating a proportionally greater role of ET-1 in supporting blood pressure at higher 
exercise intensities.  In the presence of the increased perfusion induced by ETA receptor 
blockade, there is the possibility for an enhanced washout of metabolic byproducts and 
subsequent alteration in the metabolic milieu within the exercise muscle. This could 
attenuate firing of group III and IV afferent nerves and attenuate the metaboreflex-
induced pressor response, providing an alternate explanation for the reduction in blood 
pressure in the BQ-123 trial. However,  pH and net lactate release, two important 
metabolic variables thought to stimulate group III and IV afferent nerves (20), were 
unchanged between trials (Table 3.2), increasing confidence that the observed changes in 
arterial blood pressure were directly related to ETA receptor inhibition. 
To our knowledge, this is the first study to identify a significant role of ET-1 in 
the regulation of arterial blood pressure during exercise. In animals, Maeda et al. (29) 
failed to show a change in exercising arterial blood pressure following ETA receptor 
blockade trial, though the systemic administration of the ETA receptor blocking drug 
preclude direct comparison with the present findings. It is tempting to speculate that this 
observed reduction in blood pressure demonstrates the role of the ET-1 pathway in 
protecting against the possibility of hypotension during exercise, as is seen when 
additional muscle mass is recruited at near maximal exercise intensities (10, 42, 50, 55).  
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The intensity-dependent contribution of the ETA receptor in the maintenance of 
vascular tone also plays a role in the regulation of intramuscular efficiency. Following 
ETA receptor blockade, leg oxygen consumption (VO2) during exercise increased with no 
alteration in leg arterial venous oxygen difference (a-vO2diff) (Table 3.2). Previously, it 
was thought that during exercise paradigms in which cardiac output does not limit blood 
flow to the exercising muscle, muscle was effectively overperfused (3), evident by the 
observations that the venous blood draining the exercising muscle remaining fairly 
saturated with O2 (3, 38). However, the current study is in agreement with previous work 
documenting an increase in skeletal muscle VO2 when blood flow to the exercising 
skeletal muscle was increased via stellate ganglion block (19). In light of this increase in 
leg VO2 induced by ETA receptor blockade, the absence of an alteration in net lactate 
release (Table 3.2) indicates that the restraint in oxygen delivery mediated by endogenous 
ET-1 does not play role in governing relative exercise intensity. Collectively, these data 
suggest that the ET-1 vasoconstrictor pathway appears to importantly contribute to 
optimizing O2 delivery and VO2 through restraint of skeletal muscle blood flow during 
exercise. Whether the documented increase in leg VO2 induced by ETA receptor 
inhibition in the current study is directly due to an alteration in metabolism of the 
exercising skeletal muscle or just through an enhancement of oxygen delivery requires 
further investigation. 
In many pathophysiologies, an increase in exercising limb blood flow could be 
viewed as beneficial, inasmuch as O2 delivery to the exercising tissue is improved. 
However, the cardiovascular response to exercise appears to be governed by a very 
complex combination of vasodilatory and vasoconstricting influences that optimize 
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exercising muscle perfusion while protecting arterial blood pressure. Data from the 
present study suggest that the ET-1 pathway is a significant contributor to maintaining 
this balance during exercise. Indeed, disrupting ET-1-mediated vasoconstriction via ETA 
receptor inhibition appears to produce an overall deleterious effect in the peripheral 
circulation, evidenced by the fact that BQ-123 produced an increase in limb blood flow 
that was met with a decrease in arterial blood pressure and increased O2 consumption (i.e. 
reduced efficiency) (Figures 3.2 and 3.3). When viewed in conjunction with the marked 
rise in net ET-1 release during exercise (Table 3.2), these observed responses indicate 
that ET-1 provides an important restraining influence to muscle blood flow during 
exercise, tempering the tendency of this “sleeping giant” to vasodilate at the expense of 
arterial blood pressure and intramuscular efficiency.   
 
Mechanisms Mediating ET-1 Release during Exercise 
Increases in ET-1 production has been documented to increase in response to 
increases pulsatile stretch (26), shear stress (31) and a reduction in pH (25), all of which 
occur in an intensity-dependent manner during exercise. ET-1-mediated vasoconstriction 
is thought to be primarily mediated by the ETA receptor located on vascular smooth 
muscle (33). At rest, infusion of ET-1 induces a sustained, slow-developing, long lasting 
vasoconstriction (33, 57), attributable to the influx of intracellular and extracellular 
calcium into the cytosolic space (39). The ET-1-mediated increase in cytosolic calcium 
initially occurs transiently, followed by a sustained increase in cytosolic calcium  (39). 
The rapid (30 sec), transient increase in calcium is induced via a G protein-dependent 
signal transduction pathway of phospholipase C activation, inositol triphosphate (IP3) 
generation, and the release of calcium stored in the sarcoplasmic reticulum (32). Because 
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the IP3-mediated pathway is dependent on ET-1 concentration, the exceedingly low 
concentrations of ET-1 at rest lead to the breakdown of IP3 and the reuptake of 
intracellular calcium (33).  This potentially explains the limited role of ET-1 in the 
regulation of vascular tone in the young at rest, a population that exhibits low levels of 
circulating ET-1 (Table 3.2) (27, 54). However, during exercise, where there is a 
significant increase in circulating concentrations ET-1 (Table 3.2), the ET-1-mediated 
increase in IP3 and subsequent release of intracellular calcium might explain the rapid 
alterations in the ETA receptors’ contribution to vascular tone exhibited in this study 
(Figures 3.2 and 3.3). 
 
Clinical Implications  
The importance of the ET-1 vasoconstrictor pathway in the regulation of blood 
flow to the exercising skeletal muscle may be of particular relevance in populations 
whose phenotype is associated with high circulating levels of ET-1 and an elevated ET-1 
contribution to vascular tone such as hypertension (49), heart failure (6), chronic 
obstructive pulmonary disease (12), and the geriatric population (30). All of these 
populations are associated with the same degree of exercise intolerance, which might be 
linked to the excessive increase in vascular tone induced by the ET-1 vasoconstrictor 
pathway. This raises the interesting possibility of the ET-1 pathway as being a potential 
peripheral therapeutic target to improve skeletal muscle blood flow and ultimately 
exercise tolerance in these populations, though further studies are necessary to evaluate 





Experimental Considerations  
Due to the slow acting kinetics of BQ-123 binding and clearance, the study was 
ordered so the control (saline) trial always preceded the BQ-123 trial. However, an 
exercise time control trial on a separate day demonstrated highly reproducible 
measurements of CFA blood flow and mean arterial blood pressure during repeated bouts 
of KE exercise (Figure 3.4), providing confidence in the comparison of the control and 
the BQ-123 trials. Additionally, due to the inability to correct hematocrit for trapped 
plasma volume, observed changes in net ET-1 and lactate release during exercise might 
be due to hemoconcentration induced during exercise. However, when hematocrit was 
held constant by incorporating resting hematocrit levels into the equation used to 
calculate  the net release of these two molecules, changes in net ET-1 and lactate release 
due to hemoconcentration accounted for less than one percent of the exercise-induced 
increase observed at every work rate.  Finally, we cannot exclude the possibility that 
some of the observed changes in peripheral hemodynamics are due to ET-1 subtype B 
(ETB) receptor activation, as BQ-123 is highly selective for ETA receptors. However, a 
recent study utilizing combined ETA and ETB receptor inhibition failed to identify a 
significant role for ETB receptors in the regulation of vascular tone in humans (54).  
Summary 
The present study has revealed a significant role of the ET-1 pathway in the 
cardiovascular response to exercise, implicating vasoconstriction via the ETA receptor as 
an important mechanism for both restraint of blood flow in the exercising limb and 
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FIGURE 3.1. Experimental protocol. Arrows indicate points at which leg blood flow 





























FIGURE 3.2.  Common femoral artery (CFA) blood flow (top),  mean CFA blood 
pressure (middle), and CFA vascular conductance (bottom) at rest and exercise during 
continuous infusion of saline (black circles) and BQ-123 (open circles). The intensity-
dependent increase in CFA blood flow, mean CFA blood pressure, and CFA vascular 
conductance were attenuated during ETA receptor inhibition. * Significant difference 










FIGURE 3.3. BQ-123-induced changes in femoral artery (CFA) blood flow (top), mean 
CFA blood pressure (middle), and CFA vascular conductance (bottom) at rest and during 
exercise. The contribution of the ETA receptor to CFA vascular tone and mean CFA 
blood pressure is enhanced only during exercise in an intensity-dependent manner. + 












FIGURE 3.4:  Common femoral artery (CFA) blood flow and mean arterial blood 
pressure during multiple time points in the exercise time control study are displayed. No 
significant differences were observed between measurements at rest or at equivalent 


















































Systolic blood pressure, mmHg 
 
107±5 
Diastolic blood pressure, mmHg 
 
73±3 
Quadriceps muscle mass, kg 
 
2.0±0.1 













LDL, mg/dl   78±9 
























IMPACT OF ENDOGENOUS ENDOTHELIN-1 ON THE REGULATION OF 
VASCULAR TONE AT REST AND DURING DYNAMIC  




















While the endothelin-1 (ET-1) vasoconstrictor pathway contributes significantly 
to age-related elevations in resting peripheral vascular tone, the regulatory influence of 
ET-1 during exercise in the elderly is unknown. Thus, in eight young (24 ± 2 yrs) and 
eight old (70 ± 3 yrs) healthy volunteers, we examined changes in common femoral 
artery (CFA) blood flow (ultrasound Doppler) and blood pressure during knee extensor 
exercise before and after endothelin receptor subtype A (ETA) blockade (intra-arterial 
BQ-123, 10 nmol/min/liter of thigh volume). Heart rate, CFA blood pressure, CFA 
diameter, CFA mean blood velocity, leg a-vO2diff difference, leg VO2, pH, plasma ET-1, 
and net lactate release were measured at rest and across a wide range of absolute and 
relative knee-extensor exercise intensities (0-5-10-15-20-30W and 20-40-60-80% of 
maximal work rate (WRmax)). At rest, BQ-123 evoked a significant increase in CFA 
blood flow in the old (31 ± 10%) compared to young (2 ± 7%), with no change in 
mean CFA blood pressure. During exercise, net ET-1 release across the exercising leg 
increased 3-4 fold in both groups. BQ-123 increased CFA blood flow at all exercise 
intensities (ranging from 9 to 23%) in both young and old groups. The exercise-induced 
increase in mean CFA blood pressure was reduced to a similar degree in both groups (-2 
to -10 mmHg) following BQ-123. The increase in CFA blood flow was accompanied by 
an increase in leg VO2 in both groups, suggesting a reduced efficiency following ETA 
receptor blockade. Together, these findings demonstrate distinct differences in the 






Healthy aging is associated with an elevation in vascular tone (11, 40), 
contributing to the attenuated resting skeletal muscle blood flow observed in the elderly 
(8, 25, 26, 33, 34, 48). These age-related changes in vascular tone and the associated 
decline in skeletal muscle blood flow persist during exercise (4, 26, 34, 35). Because 
adequate muscle perfusion is vital to meet the metabolic demand of the tissue and 
maintain normal muscle function at rest and during exercise, a better understanding of the 
mechanisms which contribute to the regulation of vascular tone in the elderly is essential.  
The functional consequence of these adaptations are substantial; indeed, impairment in 
perfusion of the exercising muscle may limit the capacity for physical activity, ultimately 
leading to immobility and increased risks of cardiovascular disease in the elderly (6).  
The underlying mechanisms contributing to this age-related increase in vascular 
tone, and the apparent disparity in regulation of vascular tone between resting and 
exercising states, has long been a topic of investigation. It has been established that 
resting sympathetic nervous system (SNS) activity increases with advancing age (7, 40), 
an adaptation that contributes significantly to basal vascular tone. There is also some 
evidence that this age-related increase in SNS activity persists during exercise, as an 
exaggerated increase in plasma norepinephrine spillover and elevated vascular resistance 
have been observed during supine cycling in elderly men (42). However, more recent 
studies have revealed an interesting dichotomy between rest and exercise with respect to 
age-related changes in vasoconstrictor pathways. At rest, our group (46) and others (10, 
11) have demonstrated a blunted vasoconstriction to intra-arterial administration of alpha-
adrenergic receptor agonists in the old compared to the young (11, 46), only to see these 
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responses somewhat reversed during exercise (10, 46). Contrasting responses between 
rest and exercise may also be seen in nonadrenergic pathways; ANG-II-mediated 
vasoconstriction is significantly augmented with age at rest (48), but this age-associated 
increase in sensitivity to ANG-II is abolished during exercise (48). Notably, during 
higher-intensity exercise, we have documented that both alpha-adrenergic- (46) and 
ANG-II-mediated vasoconstriction (48) are “lysed” to a similar degree in young and old. 
These findings unveil the complexities of the age-associated alterations in blood flow 
between rest and exercise, and also raise the question of what other vasoconstrictor 
pathways may be involved in blood flow regulation in this cohort. 
Recently, increased consideration has been placed on endothelin-1 (ET-1) and its 
contributing role in the age-associated increase in vascular tone. There is evidence from 
both animal and human studies for increased activity of the ET-1 pathway with 
advancing age (15, 19), which has been shown to contribute to the age-related reduction 
in resting skeletal muscle blood flow (43, 45) via the endothelin subtype A (ETA)  
receptor pathway (23, 45). Surprisingly, very few studies have sought to determine the 
role of ET-1 in the regulation of exercising skeletal muscle blood flow. Recent work in 
animals have evaluated the tonic restraint on blood flow induced by ET-1 with  ETA  as 
well as concomitant ETA and ETB receptor blockade during exercise and reported that the 
vasodilatory effects of blockade were significantly less during exercise compared to 
control and mediated primarily by the ETA receptor in the systemic circulation (30). In 
young humans, our group recently identified a substantial ET-1-mediated 
vasoconstriction during light knee-extensor exercise that was abolished as exercise 
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intensity increased (47). However, the contribution of endogenous ET-1 to the regulation 
of exercising limb blood flow was not evaluated in this study. 
In light of the evidence for an ET-1 contribution to the elevated vascular tone in 
the elderly at rest and the documented rise in ET-1 during exercise (28), the ET-1-ETA 
receptor interaction represents one potential  mechanism for the elevated vascular tone 
observed during exercise in healthy, older individuals. Therefore the current study sought 
to determine the endogenous contribution of the ETA receptor to the age-associated 
increase in vascular tone at rest and during dynamic exercise. We hypothesized that: 1) 
ETA receptor blockade would enhance resting skeletal muscle blood flow in old, but not 
young; 2) ETA receptor blockade during exercise would enhance skeletal muscle blood 
flow and reduce arterial blood pressure to a greater extent in older individuals, compared 
to their younger counterparts.  
 
Methods 
Subjects   
Eight young (24 ± 2 yrs) and eight old (70 ± 3 yrs) healthy subjects were enrolled
 
in the present study. All subjects were nonsmokers and were normally active. Subjects 
were not taking any
 
prescription medication and were free of overt cardiovascular
 
disease, as indicated by a health history. Protocol approval and written informed consent 
were obtained
 
according to the University of Utah and the Salt Lake City Veterans 
Affairs (VA) Medical Center Institutional Review Board requirements. All data 
collection took place at the VA Salt Lake City Geriatric, Research, Education, and 





Subjects reported to the UVRL at 0800 on the experimental day. After 30 min of 
supine rest, two catheters (common femoral artery (CFA) and femoral vein) were placed 
using sterile technique as previously reported  (1, 3, 51). After catheter placement, 
subjects rested for ~30 min, and then underwent the protocol as outlined in Figure 4.1. 
Due to the duration of the study, subjects were given 1/2 cup of corn flakes and 1/2 cup 
of skim milk before the start of the control (saline) trial and BQ-123 trial to prevent 
hypoglycemia (Figure 4.1). All data collection took place with subjects in a 
semirecumbent position (60° reclined), and all studies were performed in a thermoneutral 
environment.  
Owing to potential difference in maximal knee-extensor (KE) capacity in the old 
individuals compared to their young counterparts, absolute as well as relative exercise 
intensities were incorporated into the study design (Figure 4.1). The inclusion of multiple 
absolute work rates offered the advantage of viewing the ETA receptor contribution to 
vascular tone between groups in a condition where the exercising leg musculature 
performs a similar amount of mechanical work and thus a comparable metabolic cost. In 
contrast, inclusion of work rates based on percent of maximal effort afforded the 
opportunity for between-group comparisons of measurements which are influenced by 
relative exercise intensity, such as arterial blood pressure and lactate release (38).  
Due to the long lasting effects of BQ-123, the drug administration portion of the 
protocol always occurred after the saline portion of the protocol. Thus, to minimize the 
risk that the observed changes in CFA blood flow or mean arterial blood pressure was the 
consequence of an exercise ordering effect, rather than the effect of the drug per se, 
83 
 
subjects returned to the laboratory on a separate day to undergo an exercise time control 
study.  For this visit, catheters were not placed, and no drugs were administered. Apart 
from these differences, the timeline for this study was identical to the drug infusion day, 
with the addition of measurements immediately before and after a light meal to examine 
possible postprandial hemodynamic effects.  
 
Drug Infusions  
Thigh volumes were determined anthropometrically, and then used for the 
calculation of drug dosing. A selective ETA receptor antagonist (BQ-123 Clinalfa, 
Calbiochem-Novabiochem, La¨ufelﬁngen, Switzerland) was prepared in normal saline 
(0.9% NaCl) and administered intra-arterially (CFA) at 10 nmol/min/liter of thigh volume 
(infusion rates 0.8-1.5 ml/min). This dose has been documented to induce an apparent 
plateau in vasodilation in both the forearm (14, 17) and quadriceps (43), without affecting 
arterial blood pressure. BQ-123 has been documented to have a high affinity for the ETA 
receptor (18) and effectively counteracts the vasoconstrictor effect of ET-1 infusion in the 
human forearm (16). During the control trial, normal saline (0.9% NaCl) was 
administered intra-arterially into the CFA at the same infusion rates as BQ-123. 
 
Exercise Model  
The knee extensor (KE) paradigm implemented in this study has been described 
previously (2, 26, 36, 50). Briefly, subjects were seated on an adjustable chair with a 
cycle ergometer (model 828E; Monark Exercise AB, Vansbro, Sweden) positioned 
behind them. Resistance was created by applying friction to the flywheel, which was 
turned by the subject via a metal bar connected to the crank arm of the ergometer and a 
84 
 
metal boot in which the subject’s foot was placed in. Sixty contractions per minute were 
maintained at each work rate, subjects exercised at for 3 min at 0, 5, 10, and 15W, as well 
as 20, 40, 60, and 80% of their predetermined maximal work rate (WRmax) with 3 min 




Ultrasound Doppler assessments 
Measurements of CFA blood velocity
 
and vessel diameter were performed in the 
infused leg using a Logiq
 
7 ultrasound Doppler system (GE Medical Systems, 
Milwaukee, WI) operating in duplex mode. The
 
Logic 7 was equipped with a linear array 
transducer
 
operating at an imaging frequency of 14 MHz. The CFA was insonated 2-3 cm 
proximal to the bifurcation of the CFA into the superficial and deep branches. The blood 
velocity profile was obtained
 
using the same transducer with a Doppler frequency of 5 
MHz, operated in the high-pulsed repetition frequency mode (2-25 kHz). Care was taken 
to avoid aliasing the blood velocity spectra by using scale adjustments, especially during 
exercise.
 
All blood velocity measurements were obtained with the probe
 
appropriately 
positioned to maintain an insonation angle of
 
60° or less (27). The sample volume was 
maximized according to
 
vessel size and was centered within the vessel on the basis
 
of 
real-time ultrasound visualization.  
 
Common femoral artery diameter, blood velocity, and blood flow analyses 
At all sample points, arterial diameter and angle corrected, time averaged, and 




commercially available software (Logic 7). Using measured
 
arterial diameter and Vmean, 
CFA blood flow was calculated according to the equation: 
 
(Vmean ∙ π (vessel diameter/2)
2
 ∙ 60) 
 
Artery blood pressure, vascular conductance, and heart rate assessment 
Arterial blood pressure measurements were collected continuously from the 
indwelling catheter placed in CFA with the pressure transducer placed at the level of the 
catheter (Transpac IV, Abbott Laboratories).  Mean CFA blood pressure (mmHg) was 
calculated as diastolic arterial pressure + (arterial pulse pressure x 0.33). On the exercise 
time control study day, mean arterial pressure was determined noninvasively using finger 
photoplethysmography (Finometer, Finapres Medical Systems BV, Amsterdam, The 
Netherlands). CFA vascular conductance (LVC; ml/min/mmHg) was calculated as CFA 
blood flow / mean CFA blood pressure.  Heart rate was monitored from a standard three-




A lipid panel was obtained for all subjects by standard techniques. At each 
exercise intensity, samples (3-4 ml) of femoral arterial and venous blood were collected. 
1 ml of arterial and venous blood were presented anerobically to a GEM 4000 blood-gas 
analyzer and cooximeter (Instrumentation Laboratories, Bedford, MA) to obtain arterial 
and venous total hemoglobin (tHb) oxyhemoglobin, saturation (SO2), partial pressure of 





1.39 (tHb) × (SO2/100) + 0.003 × PO2 
 
 Leg oxygen consumption (VO2) (ml/min) was calculated as: 
 
(CaO2 − CvO2) * CFA blood flow 
 
where CaO2 and CvO2 represent arterial and venous oxygen content respectively. The 
remaining blood was spun down for plasma samples, and stored at -80°C until analysis.  
Plasma ET-1 concentrations were evaluated via sandwich radioimmunoassay 
(Stressgen Bioreagents). Using arterial (CA) and venous (CV) plasma ET-1 and lactate 
concentrations, with corrections for hematocrit (hct) and CFA blood flow, “net ET-1 
release” and “net lactate release” were calculated (20, 44) according to the following 
equation:   
 
 Net ET-1 or lactate release = (CV – CA) * (CFA blood flow*((101 – (hct/100)) 
 
Statistical Analyses 
Statistical analyses were performed with the use of commercially available
 
software (SigmaStat 3.10, Systat Software, Point Richmond, CA). A 2x10 mixed 
repeated measures analysis of variance (ANOVA) was used to identify significant 
changes in measured variances within and between drug conditions and between young 
and old at rest.  Multiple 2x9 mixed repeated-measures ANOVA were used to identify 
significant changes
 
in measured variables within and between drug conditions, between 
young and old, across exercise intensities, and BQ-123-induced changes. When a 
significant main effect was found (p < 0.05), the Holm-Sidak method was used for alpha 
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adjustment and post hoc analysis. Student's t-tests were used to identify significant 
differences in subject characteristics between young and old. Significance for subject 
characteristics was established
 
at 0.05.  All group data are expressed as mean ± 




Subject Characteristics  
Subject characteristics are presented in Table 4.1. 
 
BQ-123 at Rest 
In both young and old groups, the continuous administration of the endothelin-1 
(ET-1) antagonist BQ-123 (10 nmol/min/liter of thigh volume; infusion rate 0.8-1.5 
ml/min)  did not significantly change heart rate ( -2 ± 3 bpm, young;  -4 ± 2 bpm, old) 
or mean CFA blood pressure (-1 ± 3 mmHg, young;  -2 ± 2 mmHg, old) after 45 min of 
infusion. However, BQ-123 did provoke a significant increase in CFA blood flow (Figure 
4.2) and CFA vascular conductance in the old ( 0.9 ± 0.3 ml/min/mmHg), but not in the 
young ( 0.0 ± 0.4 ml/min/mmHg). Prior to BQ-123, resting CFA blood flow was 
significantly reduced in the old compared to the young (Figure 4.2), and the  BQ-123-
mediated increase  CFA blood flow effectively restored CFA blood flow in the old to that 
of the young (Figure 4.2). 
 
BQ-123 during Exercise 
During exercise, BQ-123 induced significant intensity-dependent increases in 
CFA blood flow and vascular conductance (Figures 4.3, 4.4, 4.5 and 4.6) in both the 
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young and the old. These hemodynamic changes were accompanied by an intensity-
dependent reduction in mean CFA blood pressure (Figures 4.3, 4.4, 4.5, and 4.6) in both 
groups. In both the young and the old, the vasodilation provoked by BQ-123 during 
exercise contributed to an increase in leg VO2 without an alteration in leg a-vO2diff 
(Tables 4.2 and 4.3). Additionally, a significant increase in the net ET-1 release and no 
significant change in net lactate release or pH were observed during BQ-123 infusion 
compared to the saline trial (Tables 4.2 and 4.3).  
 
Exercise Time Control Study  
15 of the original 16 subjects (n= 8 young ;  n = 7) who participated in the drug 
infusion protocol returned to the lab for an exercise time control protocol. This additional 
protocol allowed for the assessment of CFA blood flow and mean arterial blood pressure 
during multiple exercise bouts and the consequence of food consumption on 
hemodynamics without the influence of catheter insertion and drug infusions. 
Measurements were highly reproducible, with no significant differences between CFA 




The present study has identified a functional role of the endothelin-1 (ET-1) 
vasoconstrictor pathway in the regulation of vascular tone with advancing age. At rest, 
endothelin receptor subtype A (ETA) blockade reversed the age-associated reduction in 
common femoral artery (CFA) blood flow, confirming a significant contribution of ET-1 
to the apparent elevation elevated resting vascular tone in the elderly. During exercise, 
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both the young and the old exhibited a robust increase in CFA blood flow following ETA 
receptor inhibition, demonstrating a clear ET-1-mediated restraint of skeletal muscle 
blood flow. ETA blockade also attenuated the exercise-induced increase in mean CFA 
blood pressure in both young and older groups. These hemodynamic changes were 
accompanied by a comparable increase in leg VO2 in both groups, suggestive of decrease 
in intramuscular efficiency. Together, these findings have identified a clear role for the 
ETA receptor in the regulation of vascular tone during exercise that is independent of age 
or resting responses, supporting the concept that endogenous ET-1 is an important 
component in the cardiovascular response to dynamic exercise in both young and old 
healthy humans.  
 
ETA Receptor Antagonism at Rest 
An increasing number of studies from our group (13, 48)  and others (8, 11, 32, 
39) have collectively demonstrated that healthy aging is associated with a reduction in 
resting limb blood flow. Findings from the present study confirm these previous reports, 
as leg blood flow was reduced approximately 30% in the old compared to their young 
counterparts (Figure 4.2, bottom panel). As expected, the impact on ETA receptor 
blockade in peripheral hemodynamics differed significantly between groups. 
Administration of BQ-123 did not affect CFA blood flow in the young group, but 
resulted in a progressive increase in CFA blood flow in the old that ultimately restored 
flow to a level that was similar to the young (Figure 4.2). Interestingly, prior to BQ-123 
administration, net ET-1 release was similar between groups. However, following ETA 
receptor blockade, circulating ET-1 increased almost 2-fold in the old, but remained 
unchanged in the young group (Tables 4.2 and 4.3). The present findings build upon 
90 
 
recent studies reporting a significantly greater contribution of the ETA receptor to 
vascular tone in the old compared to the young (43, 45), but with the important addition 
of arterial and venous ET-1 levels, data which provide further insight concerning the 
relationship between circulating ET-1 and hemodynamic measurements. Together, these 
former and present findings present an aging vascular phenotype characterized by an 
increase in the endogenous contribution of ET-1 to vascular tone, accompanied by an 
overall increase in bound ET-1 and/or enhanced ET-1 bioavailability in older individuals.  
 
ETA Receptor Antagonism during Exercise  
From rest to exercise, perfusion of the exercising skeletal muscle increases in 
order to match the metabolic demand of the active muscle, achieved through the 
vasoconstriction of less metabolically active tissue as well as the modulation of 
vasodilator and vasoconstrictor influences in the exercising muscle (24). Although the 
mechanisms governing the regulation of skeletal muscle blood flow during exercise have 
not been fully elucidated, there is evidence in young, healthy individuals for a reduction 
in the effectiveness of both adrenergic (9, 37, 46) and nonadrenergic (5) vasoconstrictor 
pathways from rest to exercise. Importantly, we have documented a similar inhibition of 
alpha-adrenergic-(49) and ANG-II-mediated vasoconstriction (48) between young and 
old individuals during exercise, suggesting that the role of these pathways in regulation of 
exercising blood flow is not altered with advancing age. Based on these previous findings 
and on the known role of ETA inhibition to modulate vascular tone in the elderly at rest 
(Figure 4.1) (43, 45), the ET-1 pathway seems a likely contributor to blood flow 
regulation during exercise in this cohort.    
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To our knowledge, this is the first study to demonstrate a significant role of ET-1 
during exercise in healthy, older individuals. Following ETA receptor blockade, both 
young and old exhibited a progressive increase in CFA blood flow with increasing 
absolute exercise intensities (Figures 4.3 and 4.5), accompanied by an attenuation in the 
exercise-induced increase in mean CFA blood pressure (Figures 4.3 and 4.5). The BQ-
123 induced changes in CFA blood flow were similar between young and old, and 
significant differences in BQ-123 induced changes in mean CFA blood pressure with age 
were only evident during the 10W and 15W work rates (Figure 4.5). These differences in 
mean CFA blood pressure were due to the greater relative intensities these absolute work 
rates represented in the old compared to the young, which is also indicated by the 
significantly higher  net lactate release present in the old compared to the young (Tables 
4.2 and 4.3) at these respective work rates. When comparing alterations induced by ETA 
receptor blockade during relative work rates between young and old, similar results were 
unveiled: both groups exhibited similar BQ-123-induced increases in CFA blood flow 
and a reduction in the exercise-induced increase in mean CFA blood pressure (Figures 
4.4 and 4.6, right panels).  
The increase in CFA blood flow following ETA receptor blockade was 
accompanied by a comparable decline in intramuscular efficiency in both groups, as 
evident by the rise in leg oxygen consumption (VO2) (Tables 4.2 and 4.3). Similar to 
work by Joyner et al. (21), these data indicate that in the young and old, the maintenance 
of vascular tone is not only vital in the support of arterial blood pressure, but might also 
play a role in limiting the perfusion of the exercising muscle during submaximal work in 
order to prevent an exaggerated O2 delivery and ultimately an unnecessary increase in 
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VO2. In light of this increase in leg VO2 induced by ETA receptor blockade, the absence 
of an alteration in net lactate release in both the young and the old (Tables 4.2 and 4.3) 
indicates that the restraint in oxygen delivery mediated by endogenous ET-1 does not 
play role in governing relative exercise intensity. Whether the documented increase in leg 
VO2 induced by ETA receptor inhibition in the current study is directly due to an 
alteration in metabolism of the exercising skeletal muscle or just through an enhancement 
of oxygen delivery requires further investigation. 
These observed cardiovascular responses following BQ-123 are in contrast to  
recent human work examining the effect of ETA receptor blockade on limb blood flow 
during 15 min of static intermittent handgrip exercise in middle-aged hypertensive and 
normotensive individuals (29). This study reported no difference in forearm blood flow 
during exercise between the blocked and control trials in the normotensive group, 
suggesting the ETA receptor did not contribute significantly to the modulation of vascular 
tone during handgrip exercise. The present study extends these findings through use of 
clearly delineated age groups and exercise involving an ambulatory muscle group with 
significantly greater vasodilatory capacity than the arm. With this approach, we have 
identified endogenous ET-1 as an important component in the cardiovascular response to 
dynamic exercise, regardless of age.   
 
The Dichotomy of Vascular Tone Regulation with Age:  
Rest versus Exercise 
The current assessment of cardiovascular responses to ETA receptor blockade at 
rest and during exercise have provided an interesting, yet contrasting story regarding the 
role of ET-1 in the elderly. At rest, BQ-123 administration revealed a marked, ET-1-
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mediated restraint of CFA blood flow in the elderly, but the age-specific nature of this 
response was not present during exercise (Figures 4.5 and 4.6). These findings add to the 
growing number of studies utilizing vasoactive drug infusions to probe age-related 
changes in blood flow regulation, many of which have identified significant differences 
between resting and exercising responses. Indeed, while older individuals exhibit a 
reproducible reduction in resting alpha-adrenergic vasoconstriction compared to the 
young, there is evidence for both similar (49) and exaggerated (10) vasoconstriction in 
the elderly during exercise. Similarly, old individuals demonstrate an enhanced 
vasoconstriction in response to inter-arterial ANG-II at rest, while during exercise no 
age-associated differences in response to ANG-II are present (48). The mechanisms 
responsible for this unique dichotomy in responses between rest and exercise in these 
previous studies remain unclear. However, in the present study, determination of 
circulating ET-1 levels may provide some explanation for the observed differences 
between young and old following ETA receptor blockade. Specifically, BQ-123 
administration did not alter resting net ET-1 release or CFA blood flow in the young, 
while ET-1 release increased almost 2-fold in the old after BQ-123, which was 
accompanied by a ≈30% increase in CFA blood flow (Tables 4.2 and 4.3).  In contrast, 
exercise-induced changes in net ET-1 release did not differ between young and old in 
either saline or BQ-123 trial. Combined with the parallel changes in CFA blood flow, 
blood pressure (Figures 4.3 and 4.4), and VO2 (Tables 4.2 and 4.3) between groups, this 
similar rise in ET-1 release during exercise suggests an equally important role for ET-1 in 
the regulation of vascular tone between young and old, and highlights the diverse manner 
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in which endogenous vasoconstrictors such as ET-1 govern vascular tone at rest and 
during dynamic exercise. 
 
Perspectives 
In light of the nonsignificant differences in BQ-123-induced changes between the 
young and old during exercise, the ET-1 vasoconstrictor pathway still might be relevant 
in the regulation of vascular tone in the old during exercise. While aging and 
hypertension represent two independent risk factors for cardiovascular disease, aging is 
associated with increases in systolic blood pressure, diastolic blood pressure, and pulse 
pressure (22). This increase in hypertension is in part associated with increases in 
endothelial dysfunction. While most studies have focused on the age-associated changes 
in endothelial-dependent nitric oxide production (12, 31, 41), it is apparent that the ET-1 
vasoconstrictor pathway plays a significant role both in the regulation of blood pressure 
and blood flow at rest and during exercise in patients with hypertension. At rest, in 
middle-aged to older patients with essential hypertension, a nonselective endothelin 
receptor antagonist, bosentan, significantly lowered arterial blood pressure (23). 
Additionally,  the local infusion of BQ-123 in to the forearm of  middle-aged to older 
patients with essential hypertension has been documented to increase forearm blood flow 
(29), indicating that the ET-1 vasoconstrictor pathway plays a role in blood flow restraint 
during exercise in this patient population.  
 
Experimental Considerations 
Due to the slow acting kinetics of BQ-123 binding and clearance, the study was 
ordered so the control (saline) trial always preceded the BQ-123 trial. However, a time 
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control trial on a separate day demonstrated highly reproducible measurements of CFA 
blood flow and mean arterial blood pressure during repeated bouts of KE exercise (Figure 
4.5), providing confidence in the comparison of the control and the BQ-123 trials. 
Additionally, due to the inability to correct hematocrit for trapped plasma volume, a 
portion of the increase in net ET- and lactate release observed during exercise might be 
due to hemoconcentration induced during exercise. However, when hematocrit was held 
constant by incorporating resting hematocrit levels into the equation used to calculate net 
ET-1 and lactate release, changes in release of these two molecules due to 
hemoconcentration accounted for less than one percent of the exercise-induced increases 
observed at every work rate.  Finally, we cannot exclude the possibility that some of the 
observed changes in peripheral hemodynamics are due to ET-1 subtype B (ETB) receptor 
activation, as BQ-123 is highly selective for ETA receptors. However, a recent study 
utilizing combined ETA and ETB receptor inhibition have failed to identify a significant 
role for ETB receptors in the regulation of vascular tone in humans (45).  
 
Conclusions 
The findings from this study have unveiled a clear role for the ETA receptor in the 
regulation of vascular tone during exercise that is independent of age or resting 
responses, supporting the concept that endogenous ET-1 is an important component in 
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FIGURE 4.1.  Experimental protocol. Arrows indicate points at which leg blood flow 








































Figure 4.2. Resting common femoral artery (CFA) blood flow expressed as percent 
change (top panel) and absolute values (bottom panel) during continuous infusion of BQ-
123 in the young (black circles) and old (grey triangles). ‡ Significant difference from 


















FIGURE 4.3. Common femoral artery (CFA) blood flow (top), mean CFA blood 
pressure (middle), and CFA vascular conductance (bottom) at rest and  exercise of 
absolute work rates during continuous infusion of saline (filled symbols) and BQ-123 
(open symbols). * Significant difference from saline in both the young and old, P<0.05; 







































FIGURE 4.4. Common femoral artery (CFA) blood flow (top), mean CFA blood 
pressure (middle), and CFA vascular conductance (bottom) at rest and  exercise of 
relative work rates during continuous infusion of saline (filled symbols) and BQ-123 
(open symbols). * Significant difference from saline in both the young and old, P<0.05; 
**Significant difference from saline in the old, P<0.05; *** Significant difference from 











FIGURE 4.5. BQ-123-induced changes in common femoral artery (CFA) blood flow 
(top), CFA blood pressure (middle), and CFA vascular conductance (bottom) at rest and 
exercise of  absolute work rates in  young (black bars) and old (grey bars). + Significant 











FIGURE 4.6. BQ-123-induced changes in common femoral artery (CFA) blood flow 
(top), CFA blood pressure (middle), and CFA vascular conductance (bottom) at rest and 
exercise of   relative work rates in  young (black bars) and old (grey bars). + Significant 
difference from BQ-induced changes at rest in the young and old, P<0.05; ++ Significant 
difference from BQ-induced changes at rest in the old, P<0.05; +++ Significant 












FIGURE 4.7: Common femoral artery (CFA) blood flow and mean arterial blood 
pressure during the time control study in the young (black circles) and old (grey circles) 
are displayed. No significant differences were observed between measurements at rest or 





















































Table 4.1. Subject Characteristics 































































LDL, mg/dl   78±9   83±10 
HDL, high density lipoprotein; LDL, low density lipoprotein ‡ 


































































Healthy aging is associated with alterations to regulatory pathways controlling the 
cardiovascular system. While these alterations initially might not pose a threat to overall 
cardiovascular health, chronic changes might expedite the progression of cardiovascular 
disease in the geriatric population. One principle age-related change to the cardiovascular 
system is an elevation in vascular tone (2, 7), which likely contributes to the attenuated 
skeletal muscle blood flow observed at rest in the elderly (1, 3-6).  Because adequate 
muscle perfusion is vital to meet the metabolic demand of tissue and maintain normal 
muscle function at rest and during exercise, a better understanding of the mechanisms 
which contribute to the diminished blood flow in the elderly is essential.   
While there are an abundance of vasoactive molecules that might contribute to 
age-associated alterations in vascular tone at rest and during physical activity, 
angiotensin-II (ANG-II) and endothelin-1 (ET-1) represent two potentially significant 
and somewhat understudied pathways. Indeed, healthy aging is associated with an 
increase in ANG-II vasoconstrictor activity at rest (10). However, until now it was 
unknown whether the age-related increase in ANG-II-mediated vasoconstriction is 
predominately due to a hypersensitivity of the postjunctional AT1 receptors or due to an 
enhanced ANG-II potentiation of NE release and ultimate alpha-adrenergic 
vasoconstriction. ET-1 has also been documented to play a vital role in increasing 
vascular tone with age (8, 9), but the contribution of this potent endogenous 
vasoconstrictor during exercise had, until now, remained poorly defined. Thus, two 
studies were undertaken to study the role of these respective pathways on the regulation 
of vascular tone with advancing age. 
120 
 
In the first study, we aimed to determine the individual and possible potentiating 
effects of the alpha-adrenergic and renin-angiotensin-aldosterone (RAAS) pathways 
using intra-arterial infusions of ANG-II, norepinephrine (NE), and ANG-II with 
concomitant alpha-adrenergic receptor antagonism (phentolamine (PHEN)). At maximal 
doses, the ANG-II-mediated reduction in brachial (BA) blood flow was greater in the old 
compared to the young, while the NE-mediated reduction in BA blood flow was similar 
between groups. In the presence of PHEN, the ANG-II-mediated reduction in BA blood 
flow in the old was restored to that of the young. These findings highlight the key role the 
alpha-adrenergic pathway in enhancing the ANG-II-mediated reduction in skeletal 
muscle blood flow with advancing age.  
The first objective of the second study was to better characterize the role of 
endogenous endothelin-1 (ET-1) in the regulation of skeletal muscle blood flow at rest 
and during exercise in young, healthy adults. Using ET-1 receptor subtype A (ETA) 
antagonism (BQ-123), we documented no change in common femoral artery (CFA) blood 
flow at rest. During exercise, common femoral artery (CFA) blood flow and vascular 
conductance were significantly elevated in the exercising limb following ETA receptor 
inhibition, demonstrating a substantial (~20%) ETA-mediated restraint of skeletal muscle 
blood flow at the higher exercise intensities. ETA blockade also blunted the intensity-
dependent rise in CFA blood pressure produced during exercise, suggesting that the ET-1 
pathway may also play an important role in the support of blood pressure. The increase in 
CFA blood flow following BQ-123 was accompanied by an increase in leg VO2 with no 
change in a-vO2diff, effectively decreasing intramuscular efficiency. Together, these 
findings have identified a significant role of the ET-1 pathway in the cardiovascular 
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response to exercise, implicating vasoconstriction via the ETA receptor as an important 
mechanism for both restraint of blood flow in the exercising limb and support of arterial 
blood pressure in healthy, young adults. 
The second objective of the second study was to investigate the differing role of 
endogenous endothelin-1 (ET-1) in the regulation of skeletal muscle blood flow during 
exercise in the elderly compared to their younger counterparts. Using ET-1 receptor 
subtype A (ETA) antagonism (BQ-123), we documented no change in CFA blood flow in 
the young, and a ~30% increase in CFA blood flow in the old at rest. During exercise, net 
ET-1 release across the exercising leg increased ~3-fold. BQ-123 increased CFA blood 
flow by ~20% and attenuated the exercise-induced increase in mean CFA blood pressure 
by ~6% in an intensity-dependent manner. The increase in CFA blood flow was 
accompanied by a ~9% increase in leg VO2 with unchanged a-vO2diff, suggesting a 
reduced efficiency of the active muscle following ETA receptor blockade. Collectively, 
these findings exhibit distinct differences in role the ET-1 pathway place in 
cardiovascular control at rest and during exercise with advancing age.  
It is of utmost importance that we understand and study the age-associated 
changes in the cardiovascular system in order to investigate therapeutic avenues to 
improve the quality of life with advancing age. Findings from the studies contained 
herein may help to achieve this goal, as we have provided new insight into concerning the 
role the RAAS and the ET-1 pathway in the regulation of vascular tone in the elderly. We 
propose that the findings regarding the synergistic properties between the RAAS and 
adrenergic system and the ET-1 vasoconstrictor pathway not only expand our 
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understanding the physiology of aging, but also demonstrate the potential for targeting 
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